The Low Grade Neoplasia Pathway
Mara Rendi, Associate Professor, University of Washington, Seattle, WA; Hospital Pathology Associates, Minneapolis, MN
At the end of the session, participants will be able to:
- Delineate the differences between columnar cell change, columnar cell hyperplasia, and flat epithelial atypia and describe the various treatment implications
- Construct a framework to discriminate between ADH and DCIS both on core needle biopsies and on excisions
- Analyze the molecular mechanisms underlying the low grade breast neoplasia pathway and how this relates to everything from columnar cell change to LCIS to low grade carcinoma
Session Description:
In this talk we will cover the low grade neoplasia pathway including the various histologic diagnoses as well as the molecular mechanisms. Time will be spent on the evolving management of ADH, LCIS, DCIS and a practical method of making these difficult diagnoses. This session will be of value to pathology residents, PAs, general and dedicated breast pathologists.
Speaker Bio:
Mara Rendi completed her MD, PhD at Dartmouth Medical School with her PhD focusing on molecular pathways of breast carcinogenesis. She then completed her Anatomic Pathology training and a Breast and Gynecologic Pathology Fellowship at the University of Washington in Seattle, WA. After completing her fellowship, she joined the faculty at the University of Washington in Anatomic Pathology as a Breast and Gynecologic pathologist and as the director of medical education in pathology for the School of Medicine for several years. She recently moved to Minneapolis, MN and joined Hospital Pathology Associates as a breast and gynecologic pathologist and continues to participate remotely in medical education for the University of Washington.
Updates on the 8th Edition of the AJCC Breast Cancer Staging Manual
Mara Rendi, Associate Professor, University of Washington, Seattle, WA; Hospital Pathology Associates, Minneapolis, MN
At the end of the session, participants will be able to:
- Demonstrate the critical importance of biomarkers and molecular tests in the new staging system
- Illustrate the difference between the anatomic stage, pathologic prognostic stage, and clinical prognostic stage
- Describe the studies that allowed for the major changes in the staging system
- Correctly classify LCIS, microinvasion, multifocal carcinoma, lymph node metastasis, and skin involvement
Session Description:
In this talk, we will cover the changes in the 8th edition of the AJCC breast cancer staging system in a systematic way. The minor changes that affect every day pathologist workflow as well as the major inclusion of biomarkers and molecular tests will be covered. In addition, the data leading to these changes will be summarized so pathologists will understand “Why now?” This session will be of value to pathology residents, PAs, general pathologists and dedicated breast pathologists.
Speaker Bio:
Mara Rendi completed her MD, PhD at Dartmouth Medical School with her PhD focusing on molecular pathways of breast carcinogenesis. She then completed her Anatomic Pathology training and a Breast and Gynecologic Pathology Fellowship at the University of Washington in Seattle, WA. After completing her fellowship, she joined the faculty at the University of Washington in Anatomic Pathology as a Breast and Gynecologic pathologist and as the director of medical education in pathology for the School of Medicine for several years. She recently moved to Minneapolis, MN and joined Hospital Pathology Associates as a breast and gynecologic pathologist and continues to participate remotely in medical education for the University of Washington.
Special-type and Uncommon Breast Cancers
Mara Rendi, Associate Professor, University of Washington, Seattle, WA; Hospital Pathology Associates, Minneapolis, MN
At the end of the session, participants will be able to:
- Formulate the differential diagnosis of triple negative breast cancers
- Distinguish between different metaplastic breast carcinomas and their mimics
- Interpret various cases of special type breast cancers and explain the varying prognoses
Session Description:
This presentation will cover Special-type and uncommon breast cancers. Although most breast cancers that a pathologist encounters are invasive ductal and lobular carcinoma, there are numerous more rare cancers that are critical to diagnose properly as the often carry dramatically different prognoses. In this talk we will take a practical approach and will systematically cover these unusual breast cancers and elucidate important clues to the diagnoses. This session will be of value to pathology residents, PAs, general pathologists and dedicated breast pathologists.
Speaker Bio:
Mara Rendi completed her MD, PhD at Dartmouth Medical School with her PhD focusing on molecular pathways of breast carcinogenesis. She then completed her Anatomic Pathology training and a Breast and Gynecologic Pathology Fellowship at the University of Washington in Seattle, WA. After completing her fellowship, she joined the faculty at the University of Washington in Anatomic Pathology as a Breast and Gynecologic pathologist and as the director of medical education in pathology for the School of Medicine for several years. She recently moved to Minneapolis, MN and joined Hospital Pathology Associates as a breast and gynecologic pathologist and continues to participate remotely in medical education for the University of Washington.
Vascular Lesions of the Breast
Hua Yang MD, FRCPC
Speaker Bio:
Dr. Yang finished his Residency in Anatomic Pathology at Dalhousie University in Halifax. He also did Clinical Fellowship training in Breast Pathology at Mount Saint Hospital in University of Toronto.
Dr. Yang currently is a Clinical Associate Professor and the Breast Pathology Specialty Group Leader at the Department of Pathology in University of Calgary. He is also an executive member of The Provincial Breast Cancer Care Committee in the province of Alberta, Canada.
Dr. Yang is specialized in breast cancer diagnosis and cancer prognostic/predictive marker reporting. He has published 6 book chapters, 35 journal articles and numerous international meeting presentations.